Risk of osteoporotic fractures with angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in hypertensive community-dwelling elderly

Journal of Bone and Mineral Research

Volumn 29, Issue 11 S1, 2014, Pages 2483-2488

  Butt, Debra A ^a,b   Mamdani, Muhammad ^c,d,e,f   Gomes, Tara ^c,d,e,f   Lix, Lisa ^g   Lu, Hong ^c   Tu, Karen ^a,c,h  

^a UNIVERSITY OF TORONTO   (Canada)

^b SCARBOROUGH HOSPITAL   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Angiotensin ii receptor blockers; Angiotensin Converting enzyme inhibitors; Elderly; Hypertension; Osteoporosis Relatedfractures

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ANKLE FRACTURE; ANTIHYPERTENSIVE THERAPY; ARM FRACTURE; ARTICLE; CLAVICLE FRACTURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FEMUR FRACTURE; FIBULA FRACTURE; FOREARM FRACTURE; FRAGILITY FRACTURE; GERIATRIC DISORDER; GERIATRIC PATIENT; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATELLA FRACTURE; PELVIS FRACTURE; POPULATION RESEARCH; PROPENSITY SCORE; RETROSPECTIVE STUDY; RIB FRACTURE; RISK FACTOR; SHOULDER FRACTURE; SPINE FRACTURE; SURVIVAL RATE; TIBIA FRACTURE; TREATMENT DURATION; WRIST FRACTURE; CLINICAL TRIAL; FACTUAL DATABASE; FRACTURES, BONE; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DATABASES, FACTUAL; FEMALE; FRACTURES, BONE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES;

EID: 84923807286     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2271     Document Type: Article

References (20)

1. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women,men: the Framingham Heart Study. JAMA. 2002;287:1003-10.
2. Ilic K, Obradovic N, Vujasinovic-Stupar N. The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int. 2013;92:217-27.
3. Lynn H, Kwok T, Wong SYS, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone. 2006;38:584-8.
4. Rajkumar DSR, Faitelson AV, Gudyrev OS, Dubrovin GM, Pokrovski MV, Ivanov AV. Comparative evaluation of enalapril and losartan in pharmacological correction of experimental osteoporosis and fractures of its background. J Osteoporos. 2013;2013:325693.
5. Kwok T, Leung J, Zhang Y, et al. Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporos Int. 2012;23:2159-67.
6. Zhang YF, Qin L, Leung PC, Kwok TCY. The effect of angiotensinconverting enzyme inhibitor use on bone loss in elderly Chinese. J Bone Miner Metab. 2006;30:666-73.
7. Masunari N, Fujiwara S, Nakata Y, Furukawa K, Kasagi F. Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci. 2008;57:17-25.
8. Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB.J. 2008;22:2465-75.
9. Solomon D, Mogun H, Garneau K, Fischer M. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res. 2011; 26:1561-71.
10. Donmez BO, Ozdemir S, Sarikanat M, et al. Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep. 2012;64:878-88.
11. Li YQ, Ji H, Shen Y, et al. Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats. Can J Physiol Pharmacol. 2009;87:51-5.
12. Zhang YF, Qin L, Kwok TCY, Yeung BHY, Li GD, Liu F. Effect of angiotensin II type I receptor blocker losartan on bone deterioration in orchiectomized male hypertensive and normotensive rats. Chin Med J. 2013;126:2661-5.
13. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67-71.
14. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172:1739-44.
15. Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992; 45:703-14.
16. Austin PC. A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res. 2011;46: 119-51
17. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA. 2004;292:1326-32.
18. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32: 2837-49.
19. Asaba Y, Masako I, Fumoto T, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res. 2009;24:241-50.
20. Perez-Castrillon JL, Silva J, Justo I, et al. Effect of quinapril, quinaprilhydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens. 2003;16:453-9.